Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RBGLY Stock Summary
Top 10 Correlated ETFs
RBGLY
In the News
Could Reckitt spin out baby formula wing following Enfamil crisis?
Reckitt Benckiser Group PLC (LSE:RKT, ETR:3RB)'s shares continue to suffer amid a series of legal challenges related to its baby formula products. The company is facing litigation and significant financial penalties due to allegations surrounding the safety and marketing of its infant nutrition products.
Reckitt Benckiser sees modest bounce following $7.1 billion market-cap wipeout
Reckitt Benckiser saw modest gains on Monday, following the share-price slide that erased some £5.6 billion ($7.1 billion) of market value.
Enfamil maker vows to fight $60 million baby-formula verdict
Reckitt Beckinser Group said Friday it will seek to overturn a court ruling this week that awarded $60 million in damages to the family of a baby that died after being fed Enfamil infant formula, made by the British conglomerate's Mead Johnson Nutrition unit.
Reckitt unit hit with $60 million verdict in Enfamil baby formula case in Illinois
An Illinois jury has ordered Reckitt Benckiser unit Mead Johnson to pay $60 million to the mother of a premature baby who died of an intestinal disease after being fed the company's Enfamil baby formula.
Reckitt Benckiser Group plc (RBGPF) Q4 2023 Earnings Call Transcript
Reckitt Benckiser Group plc (RBGPF) Q4 2023 Earnings Call Transcript
Reckitt Benckiser shares drop 11% after sales miss and Middle East 'compliance issues'
Shares in the Nurofen maker Reckitt Benckiser Group PLC (LSE:RKT, ETR:3RB) fell 11% with the market spooked by its fourth-quarter sales miss and a £55 million revenue hit related to compliance issues at two of its Middle East operations. At 11.05 am, the stock was off 654p at 5,184p after the company revealed the trading drag was the result of lower-than-expected demand for cold and flu remedies and voluntary recall of its Nutramigen infant formula.
Reckitt shares tumble 7% on Q4 miss and revenue restatement
Reckitt Benckiser Group shares opened 7% lower after the Anglo-Dutch consumer products group's fourth-quarter performance fell short of expectations, and an understatement in trade spend that affected its full-year net revenue figure. This underperformance was attributed to reduced sales of cold and flu products during the season.
Reckitt posts like-for-like net sales drop as fewer people buy flu medication
Consumer goods group Reckitt missed fourth-quarter like-for-like net sales expectations, it said on Wednesday, citing declining sales of cold and flu season products.
Just Eat, Reckitt Benckiser, Taylor Wimpey in focus on Wednesday
Any hopes that Taylor Wimpey might 'surprise on the upside' have seemingly been dashed by the CMA probe announced this week
Reckitt Beckinser's volumes key in next week's update
Reckitt Benckiser needs to deliver improving volumes when it reports next week, according to Mark Britzman. “Third-quarter results disappointed and the concern remains that consumers have yet to fully digest higher prices,” he adds.
RBGLY Financial details
RBGLY Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2023-12-31
Metric | History | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 |
---|---|---|---|---|---|---|
2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
Revenue per share | 3.63 | 3.94 | 3.71 | 4.07 | 20.38 | |
Net income per share | -0.78 | 0.33 | -0.01 | 0.66 | 2.29 | |
Operating cash flow per share | 0.4 | 0.99 | 0.48 | 0.67 | 3.68 | |
Free cash flow per share | 0.27 | 0.85 | 0.35 | 0.55 | 3.05 | |
Cash per share | 0.39 | 0.46 | 0.35 | 0.33 | 1.94 | |
Book value per share | 2.64 | 2.56 | 2.07 | 2.66 | 11.79 | |
Tangible book value per share | -4.19 | -3.89 | -3.2 | -3.02 | 5.43 | |
Share holders equity per share | 2.64 | 2.56 | 2.07 | 2.66 | 11.79 | |
Interest debt per share | 3.53 | 3.07 | 2.75 | 2.57 | 12.04 | |
Market cap | 44.24B | 47.13B | 46.27B | 41.54B | 7.74B | |
Enterprise value | 54.89B | 56.04B | 54.57B | 49.27B | 14.89B | |
P/E ratio | -15.96 | 39.7 | -889.76 | 17.83 | 4.71 | |
Price to sales ratio | 3.44 | 3.37 | 3.5 | 2.87 | 0.53 | |
POCF ratio | 31.35 | 13.4 | 27.26 | 17.33 | 2.94 | |
PFCF ratio | 45.7 | 15.54 | 37.1 | 21.26 | 3.54 | |
P/B Ratio | 4.72 | 5.17 | 6.25 | 4.4 | 0.92 | |
PTB ratio | 4.72 | 5.17 | 6.25 | 4.4 | 0.92 | |
EV to sales | 4.27 | 4 | 4.12 | 3.41 | 1.02 | |
Enterprise value over EBITDA | 14.29 | 12.18 | 13.75 | 12.52 | 4.96 | |
EV to operating cash flow | 38.9 | 15.93 | 32.16 | 20.55 | 5.65 | |
EV to free cash flow | 56.7 | 18.48 | 43.76 | 25.21 | 6.81 | |
Earnings yield | -0.06 | 0.03 | 0 | 0.06 | 0.21 | |
Free cash flow yield | 0.02 | 0.06 | 0.03 | 0.05 | 0.28 | |
Debt to equity | 1.3 | 1.16 | 1.29 | 0.94 | 0.98 | |
Debt to assets | 0.38 | 0.34 | 0.35 | 0.31 | 0.31 | |
Net debt to EBITDA | 2.77 | 1.94 | 2.09 | 1.96 | 2.38 | |
Current ratio | 0.56 | 0.77 | 0.62 | 0.63 | 0.64 | |
Interest coverage | -5.46 | 8.66 | 14.3 | 12.64 | 7.44 | |
Income quality | -0.72 | 1.63 | -2.11 | 0.78 | 1.61 | |
Dividend Yield | 0.03 | 0.03 | 0.03 | 0.03 | 0.17 | |
Payout ratio | -0.44 | 1.05 | -23.96 | 0.54 | 0.81 | |
Sales general and administrative to revenue | 0.06 | 0.1 | 0.09 | 0.08 | 0 | |
Research and developement to revenue | 0.02 | 0.02 | 0.02 | 0.02 | 0 | |
Intangibles to total assets | 0.75 | 0.73 | 0.7 | 0.7 | 0.17 | |
Capex to operating cash flow | -0.31 | -0.14 | -0.27 | -0.18 | -0.17 | |
Capex to revenue | -0.03 | -0.03 | -0.03 | -0.03 | -0.03 | |
Capex to depreciation | -0.08 | -0.33 | -0.94 | -0.73 | -0.96 | |
Stock based compensation to revenue | 0 | 0 | 0 | 0.01 | 0 | |
Graham number | 6.82 | 4.39 | 0.82 | 6.26 | 24.66 | |
ROIC | -0.1 | 0.1 | 0.04 | 0.13 | 0.1 | |
Return on tangible assets | -0.35 | 0.14 | -0.01 | 0.27 | 0.07 | |
Graham Net | -5.38 | -5.11 | -4.47 | -4.36 | -20.73 | |
Working capital | -3.9B | -1.62B | -3.08B | -3.06B | -3.04B | |
Tangible asset value | -14.85B | -13.82B | -11.42B | -10.72B | 3.89B | |
Net current asset value | -17.7B | -16.82B | -14.49B | -13.97B | -13.37B | |
Invested capital | 1.3 | 1.16 | 1.29 | 0.94 | 0.98 | |
Average receivables | 1.07B | 2.09B | 2.06B | 2.16B | 2.19B | |
Average payables | 4.82B | 5.28B | 5.5B | 5.41B | 5.53B | |
Average inventory | 1.3B | 1.45B | 1.53B | 1.64B | 1.73B | |
Days sales outstanding | 60.8 | 53.37 | 57.39 | 56.49 | 53.52 | |
Days payables outstanding | 347.14 | 377.08 | 345.89 | 332.35 | 343.71 | |
Days of inventory on hand | 94.63 | 104.55 | 95.81 | 109.34 | 102.19 | |
Receivables turnover | 6 | 6.84 | 6.36 | 6.46 | 6.82 | |
Payables turnover | 1.05 | 0.97 | 1.06 | 1.1 | 1.06 | |
Inventory turnover | 3.86 | 3.49 | 3.81 | 3.34 | 3.57 | |
ROE | -0.3 | 0.13 | -0.01 | 0.25 | 0.19 | |
Capex per share | -0.13 | -0.14 | -0.13 | -0.12 | -0.63 |
Quarterly Fundamentals Overview
Last date of statement is 2023-12-31 for Q4
Metric | History | 2022-09-30 | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-12-31 |
---|---|---|---|---|---|---|
2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
Revenue per share | 0 | 10.57 | 5.19 | 10.39 | 0 | |
Net income per share | 0 | 1.38 | 0.86 | 1.73 | 0 | |
Operating cash flow per share | 0 | 2.18 | 0.65 | 1.3 | 0 | |
Free cash flow per share | 0 | 1.81 | 0.55 | 1.04 | 0 | |
Cash per share | 0 | 1.62 | 1.43 | 1.16 | 0 | |
Book value per share | 0 | 13.19 | 12.8 | 12.82 | 0 | |
Tangible book value per share | 0 | -14.98 | -14.14 | -14.17 | 0 | |
Share holders equity per share | 0 | 13.19 | 12.8 | 12.82 | 0 | |
Interest debt per share | 0 | 12.65 | 6.97 | 12.28 | 0 | |
Market cap | 0 | 8.36B | 8.97B | 8.63B | 0 | |
Enterprise value | -1.16B | 16.09B | 7.94B | 16.24B | 7.15B | |
P/E ratio | 0 | 2.11 | 3.64 | 1.74 | 0 | |
Price to sales ratio | 0 | 1.11 | 2.41 | 1.16 | 0 | |
POCF ratio | 0 | 5.36 | 19.18 | 9.23 | 0 | |
PFCF ratio | 0 | 6.47 | 22.68 | 11.57 | 0 | |
P/B Ratio | 0 | 0.89 | 0.98 | 0.94 | 0 | |
PTB ratio | 0 | 0.89 | 0.98 | 0.94 | 0 | |
EV to sales | 0 | 2.13 | 2.13 | 2.18 | 1 | |
Enterprise value over EBITDA | 0 | 8.52 | 7.99 | 8.17 | 7.06 | |
EV to operating cash flow | 0 | 10.32 | 16.99 | 17.37 | 4.2 | |
EV to free cash flow | 0 | 12.46 | 20.08 | 21.78 | 4.96 | |
Earnings yield | 0 | 0.12 | 0.07 | 0.14 | 0 | |
Free cash flow yield | 0 | 0.15 | 0.04 | 0.09 | 0 | |
Debt to equity | 0.73 | 0.94 | 0.54 | 0.94 | 0.98 | |
Debt to assets | 0.24 | 0.31 | 0.18 | 0.31 | 0.31 | |
Net debt to EBITDA | 0 | 4.09 | -1.03 | 3.83 | 7.06 | |
Current ratio | 0.63 | 0.63 | 0.54 | 0.54 | 0.64 | |
Interest coverage | 0 | 8.74 | 0 | 11.1 | 4.27 | |
Income quality | 0 | 1.57 | 0.75 | 0.76 | 4.23 | |
Dividend Yield | 0 | 0.06 | 0.04 | 0.09 | 0 | |
Payout ratio | 0 | 0.53 | 0.64 | 0.64 | 1.37 | |
Sales general and administrative to revenue | 0 | 0 | 0 | 0 | 0 | |
Research and developement to revenue | 0 | 0 | 0 | 0 | 0 | |
Intangibles to total assets | 0.7 | 0.7 | 0.7 | 0.7 | 0.17 | |
Capex to operating cash flow | 0 | -0.17 | -0.15 | -0.2 | -0.15 | |
Capex to revenue | 0 | -0.04 | -0.02 | -0.03 | -0.04 | |
Capex to depreciation | 0 | -0.7 | -0.62 | -0.81 | -1.1 | |
Stock based compensation to revenue | 0 | 0 | 0.01 | 0 | 0 | |
Graham number | 0 | 20.27 | 15.72 | 22.35 | 0 | |
ROIC | 0 | 0.06 | 0.05 | 0.07 | 0.02 | |
Return on tangible assets | 0 | 0.12 | 0.08 | 0.15 | 0.02 | |
Graham Net | 0 | -21.67 | -20.65 | -20.89 | 0 | |
Working capital | -3.06B | -3.06B | -4.27B | -4.27B | -3.04B | |
Tangible asset value | -10.72B | -10.72B | -10.15B | -10.15B | 3.89B | |
Net current asset value | -13.97B | -13.97B | -13.31B | -13.31B | -13.37B | |
Invested capital | 0.73 | 0.94 | 0.54 | 0.94 | 0.98 | |
Average receivables | 862M | 1.98B | 2.2B | 2.2B | 0 | |
Average payables | 3.85B | 3.96B | 5.26B | 4.98B | 0 | |
Average inventory | 1.81B | 1.83B | 1.74B | 1.66B | 0 | |
Days sales outstanding | 0 | 26.61 | 52.46 | 26.97 | 26.92 | |
Days payables outstanding | 0 | 155.18 | 296.57 | 147.6 | 175.41 | |
Days of inventory on hand | 0 | 51.06 | 98.82 | 49.18 | 52.15 | |
Receivables turnover | 0 | 3.38 | 1.72 | 3.34 | 3.34 | |
Payables turnover | 0 | 0.58 | 0.3 | 0.61 | 0.51 | |
Inventory turnover | 0 | 1.76 | 0.91 | 1.83 | 1.73 | |
ROE | 0 | 0.1 | 0.07 | 0.14 | 0.05 | |
Capex per share | 0 | -0.37 | -0.1 | -0.26 | 0 |
RBGLY Frequently Asked Questions
What is Reckitt Benckiser Group plc stock symbol ?
Reckitt Benckiser Group plc is a GB stock and trading under the symbol RBGLY
What is Reckitt Benckiser Group plc stock quote today ?
Reckitt Benckiser Group plc stock price is $11.15 today.
Is Reckitt Benckiser Group plc stock public?
Yes, Reckitt Benckiser Group plc is a publicly traded company.